Thirteen patients who progressed on the monotherapy arm crossed over to the combination arm. MK-7684 (dose range: 2.1, 7, 21, 70, 210 and 700 mg) and KEYTRUDA (200 mg fixed dose) were administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results